Víctor Cervera-Carrascón

1.1k total citations
40 papers, 761 citations indexed

About

Víctor Cervera-Carrascón is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, Víctor Cervera-Carrascón has authored 40 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 36 papers in Genetics and 17 papers in Immunology. Recurrent topics in Víctor Cervera-Carrascón's work include Virus-based gene therapy research (36 papers), CAR-T cell therapy research (35 papers) and Immunotherapy and Immune Responses (14 papers). Víctor Cervera-Carrascón is often cited by papers focused on Virus-based gene therapy research (36 papers), CAR-T cell therapy research (35 papers) and Immunotherapy and Immune Responses (14 papers). Víctor Cervera-Carrascón collaborates with scholars based in Finland, Netherlands and France. Víctor Cervera-Carrascón's co-authors include Akseli Hemminki, Riikka Havunen, João M. Santos, Anna Kanerva, Mikko Siurala, Suvi Sorsa, Sadia Zafar, Dafne C.A. Quixabeira, Camilla Heiniö and Siri Tähtinen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Víctor Cervera-Carrascón

40 papers receiving 753 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Víctor Cervera-Carrascón Finland	18	597	513	249	245	167	40	761
Suvi Sorsa Finland	13	623 1.0×	486 0.9×	239 1.0×	220 0.9×	140 0.8×	22	725
Mari Hirvinen Finland	13	550 0.9×	651 1.3×	361 1.4×	236 1.0×	196 1.2×	19	878
Timo Joensuu Finland	18	668 1.1×	716 1.4×	367 1.5×	190 0.8×	176 1.1×	27	893
Margaret R. Duffy United Kingdom	14	445 0.7×	500 1.0×	386 1.6×	134 0.5×	83 0.5×	25	705
Simona Bramante Finland	11	403 0.7×	429 0.8×	232 0.9×	152 0.6×	127 0.8×	12	601
Robert Hans Ingemar Andtbacka United States	15	716 1.2×	375 0.7×	274 1.1×	382 1.6×	77 0.5×	41	794
Tuuli Ranki Finland	16	469 0.8×	559 1.1×	402 1.6×	95 0.4×	186 1.1×	22	716
Sarah Knocke Germany	8	341 0.6×	256 0.5×	146 0.6×	210 0.9×	67 0.4×	8	488
Lotta Kangasniemi Finland	16	685 1.1×	840 1.6×	542 2.2×	145 0.6×	243 1.5×	24	1.0k
Petri Nokisalmi Finland	8	318 0.5×	355 0.7×	208 0.8×	83 0.3×	95 0.6×	12	470

Countries citing papers authored by Víctor Cervera-Carrascón

Since Specialization

Citations

This map shows the geographic impact of Víctor Cervera-Carrascón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Víctor Cervera-Carrascón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Víctor Cervera-Carrascón more than expected).

Fields of papers citing papers by Víctor Cervera-Carrascón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Víctor Cervera-Carrascón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Víctor Cervera-Carrascón. The network helps show where Víctor Cervera-Carrascón may publish in the future.

Co-authorship network of co-authors of Víctor Cervera-Carrascón

This figure shows the co-authorship network connecting the top 25 collaborators of Víctor Cervera-Carrascón. A scholar is included among the top collaborators of Víctor Cervera-Carrascón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Víctor Cervera-Carrascón. Víctor Cervera-Carrascón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peltola, Katriina, Tuomo Alanko, Teijo Pellinen, et al.. (2025). Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 13(1). e010493–e010493. 2 indexed citations

Grönberg-Vähä-Koskela, Susanna, Dafne C.A. Quixabeira, João M. Santos, et al.. (2025). Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer Immunology Immunotherapy. 74(7). 234–234. 1 indexed citations

Quixabeira, Dafne C.A., Susanna Grönberg-Vähä-Koskela, Camilla Heiniö, et al.. (2023). An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage. Frontiers in Immunology. 14. 1171083–1171083. 4 indexed citations

Quixabeira, Dafne C.A., Riikka Havunen, João M. Santos, et al.. (2023). Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Cancer Gene Therapy. 30(12). 1679–1690. 6 indexed citations

Quixabeira, Dafne C.A., Riikka Havunen, João M. Santos, et al.. (2023). Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine. Cancer Gene Therapy. 30(11). 1543–1553. 7 indexed citations

Dréno, Brigitte, Víctor Cervera-Carrascón, Eva Ellebæk, et al.. (2023). 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial. Immuno-Oncology Technology. 20. 100521–100521. 1 indexed citations

Santos, João M., Dafne C.A. Quixabeira, Susanna Grönberg-Vähä-Koskela, et al.. (2022). Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors. Molecular Therapy — Oncolytics. 28. 59–73. 8 indexed citations

Heiniö, Camilla, Víctor Cervera-Carrascón, João M. Santos, et al.. (2022). Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology. 13. 794251–794251. 32 indexed citations

Quixabeira, Dafne C.A., Víctor Cervera-Carrascón, João M. Santos, et al.. (2022). Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. OncoImmunology. 11(1). 2028960–2028960. 14 indexed citations

10.

Quixabeira, Dafne C.A., João M. Santos, Víctor Cervera-Carrascón, et al.. (2021). Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. Human Gene Therapy. 32(3-4). 178–191. 9 indexed citations

11.

Quixabeira, Dafne C.A., Sadia Zafar, João M. Santos, et al.. (2021). Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in Immunology. 12. 674400–674400. 28 indexed citations

12.

Svane, Inge Marie, João M. Santos, Víctor Cervera-Carrascón, et al.. (2021). 1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes. Annals of Oncology. 32. S864–S864. 4 indexed citations

13.

Zafar, Sadia, Dafne C.A. Quixabeira, João M. Santos, et al.. (2020). Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. Human Gene Therapy. 32(3-4). 192–202. 21 indexed citations

14.

Heiniö, Camilla, Riikka Havunen, João M. Santos, et al.. (2020). TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. Cells. 9(4). 798–798. 33 indexed citations

15.

Santos, João M., Camilla Heiniö, Víctor Cervera-Carrascón, et al.. (2020). Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. Journal for ImmunoTherapy of Cancer. 8(1). e000188–e000188. 56 indexed citations

16.

Cervera-Carrascón, Víctor, Riikka Havunen, & Akseli Hemminki. (2019). Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. Expert Opinion on Biological Therapy. 19(5). 443–455. 27 indexed citations

17.

Cervera-Carrascón, Víctor, Mikko Siurala, João M. Santos, et al.. (2018). TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. OncoImmunology. 7(5). e1412902–e1412902. 90 indexed citations

18.

Havunen, Riikka, João M. Santos, Suvi Sorsa, et al.. (2018). Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 11. 109–121. 45 indexed citations

19.

Santos, João M., Víctor Cervera-Carrascón, Riikka Havunen, et al.. (2018). Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Molecular Therapy. 26(9). 2243–2254. 44 indexed citations

20.

Siurala, Mikko, Riikka Havunen, Dipongkor Saha, et al.. (2016). Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Molecular Therapy. 24(8). 1435–1443. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact